top of page
  • Shashi

Allogeneic MSCs in treatment of Frailty Syndrome

Updated: Jan 8, 2019

"Chronic diseases and degenerative conditions are strongly linked with the geriatric syndrome of frailty and account for a disproportionate percentage of the health care budget. Frailty increases the risk of falls, hospitalization, institutionalization, disability, and death. Although exercise and nutritional supplementation provide benefit to frail patients, there are currently no specific therapies for frailty." A phase I and Phase II clinical trial CRATUS found intravenous allogeneic MSCs safe in individuals with aging frailty and produced significant benefits in measures of physical performance as well as inflammatory biomarkers.

#research #science


Recent Posts

See All

Chronic heart failure is the most common reason for hospital admissions and one of the most frequent causes of death in the western world. Scientists around the world are therefore working on strategi

"Autoimmune diseases, chronic in nature, are generally hard to alleviate. Present long-term treatments with available drugs such as steroids, immune-suppressive drugs, or antibodies have several debil

bottom of page